14 August 2024 | 7:40AM HKT Sino Biopharmaceutical (1177.HK): Earnings Review: 1H results beat with margin improvements; Highlight potential in analgesia field; Buy 1H beats on expenses saving / one-off gains: 1H24 sales of Rmb15.9bn (+11% y/y vs GSe Rmb15.3bn) was better than our expectations, mainly coming from 1) strong growth in oncology (+19.5% y/y) benefited from smooth ramp-up of newly launched products including F-627 (G-CSF) and four biosimilar drugs (Rituxan/Humira/Avastin/Herceptin), 2) solid gro ...

报告行业投资评级 SJVN Ltd.的12个月目标价为75卢比,暗示2026财年的市净率为1.8倍,低于历史平均水平的1倍 [7] 报告的核心观点 1) SJVN Q1FY25的调整后合并净利润同比增长37%,至约36亿卢比,主要得益于水电发电量同比增长54% [2] 2) 太阳能发电量同比增长240%,反映SJVN在可再生能源装机方面的推进 [2] 3) 管理层需要就Arun III水电和Buxar热电项目的执行情况、阿鲁纳恰尔邦5GW水电项目的资本支出和时间表、可再生能源业务的管线、执行和变现计划等提供更新 [3] 4) 抽水蓄能项目在密藏邦的最新进展、商业模式、资本支出和执行时间表也值得关注 [3] 分部总结 水电业务 - 水电发电量同比增长54%,反映水流量恢复正常 [2] - 管理层需要就Arun III水电项目的进展和电力购销协议提供更新 [3] - 阿鲁纳恰尔邦5GW水电项目的资本支出和执行时间表也需要关注 [3] 可再生能源业务 - 太阳能发电量同比增长240%,显示SJVN在可再生能源领域的布局 [2] - 管理层需要就可再生能源业务的管线、执行和变现计划提供更新 [3] 抽水蓄能业务 - 密藏邦抽水蓄能项目的最新进展、商业模式、资本支出和执行时间表值得关注 [3]

14 August 2024 | 8:39AM AEST Seven West Media (SWM.AX): FY24 First Take: Soft result and outlook; Sept/Oct booking trends below; Buy-back not renewed; Sell Key points: SWM reported FY24 Sales/EBITDA/NPAT -5%/-33%/-47% vs. pcp to A$1,415mn/A$187mn/A$78mn, which was +1%/-3%/-8% vs. GSe (EBITDA -4% vs. Visible Alpha Consensus Data). Cash conversion remains weak (GOCF of A$77mn, = 41% of EBITDA) (1H24 GOCF of A$89.7mn, = 72% of EBITDA) impacted by the ARN acquisition, while Net Debt to EBITDA increased to 1.6x ...

13 August 2024 | 5:11PM BST Sell 2131d4eaf4cb4d50b1d51c8af07b64b4 Pandora (PNDORA.CO) Post 2Q24: Top-line strength continues, forward setup incrementally more difficult; Sell on valuation PNDORA.CO 12m Price Target: Dkr1,060.00 Price: Dkr1,041.00 Upside: 1.8% Pandora reported 2Q24 results (August 12), with solid 2Q organic top-line growth (+15%, vs. Visible Alpha Consensus Data at +12%), and recent LFL trading driving a +1.5% FY24 organic revenue guidance upgrade at the midpoint (+9-12% organic, vs. +8-10% ...

13 August 2024 | 9:59PM BRT 2131d4eaf4cb4d50b1d51c8af07b64b4 Rede D'Or (RDOR3.SA): 2Q24 First Take: Solid operational KPIs across the board; Reiterate Buy RDOR's 2Q24 consolidated EBITDA grew 28% YoY and was in line with GSe; solid KPIs in hospital and insurance divisions. While consolidated operational performance was in line with our expectation, we note some positive KPIs in the result that we read as positive. We highlight: 1) compelling hospital EBITDA margin expansion of 1.0 pp YoY even with a 2% decl ...

报告行业投资评级 - 报告给予Pro Medicus Ltd.(PME.AX)公司"Buy"评级 [8][9] 报告的核心观点 - PME是一家云原生的放射影像存储和通信系统(PACS)软件运营商,主要业务在美国、澳大利亚和欧洲 [8] - PME的Visage 7软件是行业领先的解决方案,具有速度和云功能两大优势,影响了客户选择PACS供应商的决定 [8] - PME正在向AI和心脏病学等相邻解决方案拓展,这可能带来重大上行空间,因为PME是放射学领域的技术领导者,并且有望在这两个市场获得份额 [8] - PME预计未来将获得更多大型和高知名度的合同,并从这些新客户带来的交易量大幅增加中获益 [2] - PME认为其EBIT利润率是可持续的,未来不会有重大偏离 [2] 财务数据总结 - PME报告了FY24财年销售收入/EBITDA/净利润同比增长29%/31%/37%至A$162百万/A$120百万/A$83百万,分别超出高盛预测1%/1%/5% [1] - EBITDA超出Visible Alpha共识预测2% [1] - PME预计未来交易量将大幅增加,EBIT利润率将从FY24的69.1%扩大79个基点至FY25的69.9% [2]

13 August 2024 | 6:18PM JST 2131d4eaf4cb4d50b1d51c8af07b64b4 Rakus Co. (3923.T) Buy Earnings Review: 1Q profits above expectations; cloud sales momentum improving; Buy 3923.T 12m Price Target: ¥2,900 Price: ¥1,912 Upside: 51.7% Norihiro Miyazaki +81(3)4587-9842 | norihiro.miyazaki@gs.com Goldman Sachs Japan Co., Ltd. Ryohei Kurita +81(3)4587-1799 | ryohei.kurita@gs.com Goldman Sachs Japan Co., Ltd. Rakus's 1Q3/25 operating profits of ¥2.3 bn, reported after the August 13 close, were slightly above our estim ...

报告行业投资评级 - 报告给予Orora Ltd.(ORA.AX)股票"Buy"评级 [11] 报告的核心观点 - Orora Ltd.的2024财年EBIT(不含Saverglass)为3.23亿澳元,超过公司指引范围3.07-3.17亿澳元,高于高盛和Visible Alpha共识预测5%/6% [1] - Orora Ltd.北美业务收入为29.81亿澳元,略高于高盛预测约2%,EBIT为1.67亿澳元,高于预测5% [2] - Orora Ltd.澳大利亚和新西兰业务收入为10.11亿澳元,略低于预测2%,EBIT为1.56亿澳元,高于预测3%/2% [3] - Saverglass业务2024财年EBITDA(不含AASB16)为8500万欧元,处于8400-8800万欧元指引区间下限,受2H产量下降11%拖累 [4] 业务展望 - Orora Ltd.预计OPS业务2H2024的EBIT水平将与当前基本持平 [5] - Orora Ltd.预计澳大利亚和新西兰业务EBIT将略有下降,低于高盛预测的5% [6] - Orora Ltd.预计将在2025年初结束去库存周期,2025财年EBITDA将达1.45亿欧元 [7] - Orora Ltd.正在就潜在出售OPS业务进行讨论 [10]

13 August 2024 | 7:59PM BRT 2131d4eaf4cb4d50b1d51c8af07b64b4 Oncoclinicas (ONCO3.SA): 2Q24 first take: High organic cash consumption on still-pressured receivables ONCO's EBITDA was virtually in line with our expectation, but financial results and minority interest were weaker than expected; recurring cash consumption was worse than expected on receivables pressure. We note that reported net income for controlling shareholders of BRL 3mn missed GSe of BRL 60mn for the abovementioned reasons below EBITDA, wh ...

报告行业投资评级 ON Holding (ONON)的评级为Buy [16] 报告的核心观点 1) ON Holding在2Q24实现了强劲的业绩表现,净销售额增长27.8%,毛利率达59.9% [3] 2) 各地区销售表现良好,EMEA、美洲和亚太地区分别实现了22.2%、25.8%和84.7%的同比增长 [4] 3) 公司维持了2024财年30%以上的同比销售增长目标,毛利率预计维持在60%左右,调整后EBITDA利润率预计在16%-16.5%之间 [5] 4) 分析师预计2024-2025财年公司的同比销售增长将达到30%/26.1%,毛利率和调整后EBITDA利润率也将保持稳定 [6] 5) 分析师将公司12个月目标价上调至50美元,对应2026年26倍EV/EBITDA估值水平 [7] 分组1 - 公司在DTC渠道的销售增长放缓至30%左右,主要受到美国短期供应链制约的影响 [2][3] - 分析师预计未来公司DTC销售占比将从2024年的40%提升至2031年的51%,同时毛利率也将提升至63% [29][30][31] 分组2 - 公司长期目标是实现63%的毛利率和18%的EBIT利润率,与同行业公司相比具有较高的盈利能力 [33][34] - 分析师预计公司未来几年的EBITDA增长率和估值水平均优于同行业公司 [41][42]